Genetic Co-Administration of Soluble PD-1 Ectodomains Modifies Immune Responses against Influenza A Virus Induced by DNA Vaccination.
DNA adjuvants
DNA vaccine
checkpoint blockade
immunomodulation
influenza A
intramuscular electroporation
soluble PD-1
soluble PD-L1
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
01 Oct 2020
01 Oct 2020
Historique:
received:
10
08
2020
revised:
22
09
2020
accepted:
23
09
2020
entrez:
6
10
2020
pubmed:
7
10
2020
medline:
7
10
2020
Statut:
epublish
Résumé
Due to the low efficacy and the need for seasonal adaptation of currently licensed influenza A vaccines, the importance of alternative vaccination strategies is increasingly recognized. Considering that DNA vaccines can be rapidly manufactured and readily adapted with novel antigen sequences, genetic vaccination is a promising immunization platform. However, the applicability of different genetic adjuvants to this approach still represents a complex challenge. Immune checkpoints are a class of molecules involved in adaptive immune responses and germinal center reactions. In this study, we immunized mice by intramuscular electroporation with a DNA-vaccine encoding hemagglutinin (HA) and nucleoprotein (NP) of the influenza A virus. The DNA-vaccine was applied either alone or in combination with genetic adjuvants encoding the soluble ectodomains of programmed cell death protein-1 (sPD-1) or its ligand (sPD-L1). Co-administration of genetic checkpoint adjuvants did not significantly alter immune responses against NP. In contrast, sPD-1 co-electroporation elevated HA-specific CD4
Identifiants
pubmed: 33019546
pii: vaccines8040570
doi: 10.3390/vaccines8040570
pmc: PMC7712647
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Union's Horizon 2020
ID : No. 681137
Organisme : Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of the University of Erlangen-Nuremberg
ID : Project A73
Références
Curr Opin Virol. 2019 Feb;34:1-9
pubmed: 30497050
Int J Parasitol. 2003 May;33(5-6):457-67
pubmed: 12782047
Vet Res. 2019 Oct 10;50(1):78
pubmed: 31601266
Virol J. 2009 Mar 13;6:30
pubmed: 19284639
Lancet. 2003 Oct 25;362(9393):1353-8
pubmed: 14585636
Nat Rev Immunol. 2018 Feb;18(2):91-104
pubmed: 28990586
Vaccine. 2001 Mar 21;19(17-19):2647-56
pubmed: 11257404
PLoS One. 2020 Apr 3;15(4):e0231138
pubmed: 32243477
J Virol. 1986 Feb;57(2):623-8
pubmed: 2418215
Viruses. 2019 Feb 13;11(2):
pubmed: 30781796
Vaccine. 2001 Mar 21;19(17-19):2461-7
pubmed: 11257378
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
J Virol. 2013 Dec;87(23):12916-24
pubmed: 24067957
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Clin Invest. 2008 Oct;118(10):3273-5
pubmed: 18802488
Clin Infect Dis. 2020 Jul 11;71(2):422-425
pubmed: 31680143
Lancet. 2011 Dec 3;378(9807):1917-30
pubmed: 22078723
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
PLoS One. 2013 Aug 14;8(8):e72217
pubmed: 23967287
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
J Immunol. 2015 Nov 15;195(10):4861-72
pubmed: 26466954
Front Microbiol. 2020 Feb 07;11:135
pubmed: 32117155
Front Immunol. 2018 Jul 09;9:1568
pubmed: 30038621
Vaccines (Basel). 2020 Jan 14;8(1):
pubmed: 31947643
Vaccine. 2008 Sep 12;26 Suppl 4:D49-53
pubmed: 19230160
Expert Rev Vaccines. 2009 Sep;8(9):1251-76
pubmed: 19722897
Science. 2009 Oct 30;326(5953):734-6
pubmed: 19900932
PLoS Pathog. 2008 May 02;4(5):e1000058
pubmed: 18451985
Nature. 2006 Sep 21;443(7109):350-4
pubmed: 16921384
Clin Exp Vaccine Res. 2015 Jan;4(1):1-10
pubmed: 25648133
Biochem Biophys Res Commun. 2008 Jun 20;371(1):168-71
pubmed: 18424263
Vaccines (Basel). 2018 Mar 30;6(2):
pubmed: 29601497
Vaccine. 2010 Apr 26;28(19):3273-7
pubmed: 20206668
Nat Med. 2006 Oct;12(10):1198-202
pubmed: 16917489
Immunity. 2018 Aug 21;49(2):264-274.e4
pubmed: 30076099
Lancet Infect Dis. 2012 Jan;12(1):36-44
pubmed: 22032844
Mucosal Immunol. 2018 Jul;11(4):1265-1278
pubmed: 29545648
Vaccine. 2007 Sep 28;25(39-40):6852-62
pubmed: 17719149
Elife. 2019 Nov 15;8:
pubmed: 31729316
Virus Res. 2012 Aug;167(2):219-25
pubmed: 22609252
Asian Pac J Cancer Prev. 2012;13(8):4031-6
pubmed: 23098512
J Virol. 2014 Apr;88(8):3997-4007
pubmed: 24453366
Cell Host Microbe. 2020 Apr 8;27(4):507-518
pubmed: 32272076
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
J Immunother. 2011 Apr;34(3):297-306
pubmed: 21389868
Eur J Immunol. 2015 Apr;45(4):1019-29
pubmed: 25630305
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Nat Commun. 2020 Feb 19;11(1):948
pubmed: 32075963
Hum Vaccin Immunother. 2018 Mar 4;14(3):550-564
pubmed: 29232151
J Virol. 2005 Feb;79(3):1701-12
pubmed: 15650195
Vaccine. 2012 Dec 14;30(52):7658-61
pubmed: 23084848
J Immunother Cancer. 2018 May 22;6(1):40
pubmed: 29789020
Nat Immunol. 2010 Jun;11(6):535-42
pubmed: 20453843
Viruses. 2019 Jun 02;11(6):
pubmed: 31159488
Vaccine. 1999 Nov 12;18(7-8):623-32
pubmed: 10547421